CFR Chemaphor Inc.

Chemaphor Inc. (TSX VENTURE:CFR), a wellness company focused on Natural Health
Enhancer (NHE) products for animals and humans today announced that it has
launched a stem cell regenerative therapy for pets and horses in Canada.
Chemaphor will be offering this treatment through veterinarians and expects to
generate revenues this year. Chemaphor has gained access to the exclusive
marketing rights for this procedure in Canada through the acquisition of 7552882
Canada Inc., a private company. The ultimate licensor of this regenerative stem
cell therapy is Vet-Stem, Inc. of California. 


Paul Dick, CEO of Chemaphor, highlighted that "this is a fantastic opportunity
to combine a novel, demonstrably effective treatment for suffering pets and
their owners, while maintaining our focus on providing scientifically supported
solutions to veterinarians and their patients. Prior to deciding on our first
acquisition, we consulted with academic institutions, veterinarians, surgeons
and other third parties in determining the fit of this opportunity with
Chemaphor and its valued customers. We are delighted that we can now look
towards implementing this procedure across Canada. Furthermore, this opportunity
complements the Oximunol(TM) Chewables product commercialization program that,
together with the ongoing program to commercialize a non-antibiotic feed
additive for food animals, shows Chemaphor is putting in place a pipeline of NHE
products for animal health". 


David Hankinson, Chairman of Chemaphor added, "We are advancing our pipeline
assertively while keeping an eye on potential value-creating opportunities in
the hope of rewarding our investors, who have been tremendously patient with our
product development timelines. This stem cell regenerative treatment is exciting
and allows us to confirm to our shareholders that we are now a commercial
organization, with a market approved therapy complemented by a pipeline of
Chemaphor-owned products. Chemaphor's launch of a stem cell regenerative
treatment in Canada allows us to build and foster relationships with
veterinarians, with the knowledge that we have proprietary products that might
be complimentary to that sales channel." Mr. Hankinson also added, "We hope to
layer on additional products and recruit key people to support our commercial
infrastructure and growth, transforming Chemaphor into a wellness company with
products in development and, now, on the market." 


The regenerative treatment being launched in Canada by Chemaphor is delivered by
harnessing an animal's own stem cells taken from a small fat tissue sample,
which Chemaphor will process at its laboratories in PEI, allowing many of the
more than 10,000 veterinarians in Canada to deliver a procedure that assists in
repairing damaged joints or ligaments through a regenerative process. 


The purchase price paid by Chemaphor for its acquisition of all of the issued
and outstanding shares of 7552882 Canada Inc. was 4,500,000 Chemaphor common
shares having a value of $495,000, based on the closing price of Chemaphor
Common Shares on the TSX Venture Exchange on June 18, 2010, the last closing
price prior to closing of the acquisition. The Chemaphor shares issued to the
shareholders of 7552882 Canada Inc. were placed into an escrow on closing and
will be released in accordance with the following schedule: 30% on August 31,
2010, 30% on November 30, 2010, 25% on February 28, 2011 and 15% on the second
anniversary of the closing of the acquisition.


About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering natural
health enhancer ("NHE") products to humans and animals to assist in optimizing
health and daily quality of life. Chemaphor is advancing NHE product candidates
for the food animal market, companion animal market and various, potential human
applications. More information can be found at www.chemaphor.com. 


Forward Looking Statements

This news release includes certain forward-looking statements that are based
upon current expectations, which involve risks and uncertainties associated with
Chemaphor's business and the environment in which the business operates. Any
statements contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the expressions
"anticipate", "believe", "plan", "estimate", "expect", "intend", and similar
expressions to the extent they relate to Chemaphor or its management. The
forward-looking statements are not historical facts, but reflect Chemaphor's
current expectations regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that could cause
actual results or events to differ materially from current expectations.
Chemaphor assumes no obligation to update the forward-looking statements, or to
update the reasons why actual results could differ from those reflected in the
forward-looking statements.

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024

Chemaphor Inc. (TSXV:CFR)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024